![](/images/graphics-bg.png)
Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
Joint Authors
Kim, Dong Yoon
Chae, Ju Byung
Kim, Jin Young
Kim, Jisoo
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-07-22
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Purpose.
To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC).
Methods.
A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg once per day for at least 1 month.
The primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment.
Secondary outcomes included central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) changes after spironolactone treatment.
Results.
Seventeen eyes from 15 patients were included in this study.
Conditions warranting chronic systemic steroid use were myasthenia gravis (6/15, 40%), glomerulonephritis (5/15, 33.3%), and organ transplantation (4/15, 26.7%).
Mean symptom duration of CSC was 4.00 ± 3.04 months.
After spironolactone treatment, 14 eyes (82.4%) showed complete resolution of SRF (P<0.001) without discontinuation of systemic steroid.
CST and BCVA were significantly improved after spironolactone treatment.
SFCT was significantly decreased after spironolactone treatment.
No patients experienced electrolyte imbalance after spironolactone treatment.
Conclusion.
MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients.
This treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions.
American Psychological Association (APA)
Kim, Jin Young& Chae, Ju Byung& Kim, Jisoo& Kim, Dong Yoon. 2018. Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment. Journal of Ophthalmology،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1196546
Modern Language Association (MLA)
Kim, Jin Young…[et al.]. Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment. Journal of Ophthalmology No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1196546
American Medical Association (AMA)
Kim, Jin Young& Chae, Ju Byung& Kim, Jisoo& Kim, Dong Yoon. Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment. Journal of Ophthalmology. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1196546
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1196546